Spravato (Esketamine) 56mg Nasal Spray Dose...
This dataset captures the breakthrough clinical data associated with the Spravato (Esketamine) 56mg Nasal Spray Dose Kit. As a revolutionary alternative to traditional SSRIs and SNRIs, Spravato represents a paradigm shift in mental health treatment. The dataset is meticulously curated to align with the analytical standards of the National Institute for Applied Statistics Research Australia (NIASRA) and the University of Wollongong (UOW), providing a robust foundation for studying rapid-acting psychiatric interventions.
Clinical & Technical Significance The information detailed in this dataset is pivotal for:
• Glutamate System Modulation: Understanding how targeting the brain’s most abundant excitatory neurotransmitter can “reset” overactive anxious states.
• Precision Dosing Analysis: Evaluating the efficacy of the 56mg dose kit (2x28mg devices) in maintaining consistent therapeutic levels.
• Long-Term Remission Studies: Providing data for the transition from induction phases to weekly or bi-weekly maintenance sessions.
There are no views created for this resource yet.
Additional Information
| Field | Value |
|---|---|
| Data last updated | 26 June 2026 |
| Metadata last updated | 26 June 2026 |
| Created | 26 June 2026 |
| Format | JPEG |
| License | No License Provided |
| Datastore active | False |
| Has views | False |
| Id | 002ec3cc-d7ee-4c27-9ed8-c93b0d44e23f |
| Mimetype | image/jpeg |
| Package id | 5bc0de6f-a47a-4e87-882f-013470014d94 |
| Position | 0 |
| Size | 17.8 KiB |
| State | active |
| Url type | upload |